Abstract:Abstract Introduction GLP-1 receptor agonist is a medication class that mimics the endogenous incretin hormone GLP-1. Short-acting GLP-1 agents were studied as adjunct therapies in type 1 diabetes (T1DM) but not approved due to concern of increased diabetic ketoacidosis (DKA) risk. Long-acting GLP-1 medications are still commonly prescribed for T1DM patients. One study has assessed the impact of a long-acting GLP-1 in 11 T1DM patients. No hospitalizations were observed, and time in range was not reported. [1] Our study aims to evaluate the efficacy and safety of long-acting GLP-1 medications in a larger cohort of T1DM patients. Methodology We conducted a retrospective chart review of T1DM patients taking a long-acting GLP-1 for at least three months. ICD-10 code E10. Type 1 diabetes mellitus was used to search our institution's Electronic Health Record system (EPIC). Primary parameters collected included A1C and glycemic trends. Data analysis was done by averaging values over a two-year period before and after starting the medication. Results We identified 27 participants with T1DM (mean age 42yrs, mean T1DM duration 18.1yrs) on a long-acting GLP-1 (semaglutide 70.4%, dulaglutide 33.3%, long-acting exenatide 3.7%, albiglutide 3.7%). Mean therapy duration was 24.28±19. 01mo. A1C values decreased significantly from7.61±1. 08% to 7.16±0.73% (p=0. 015, N=25). Per CGM data, average time in range (TIR) increased significantly from48.82±22.35% to64.70±16.58% (p=0. 0002, N=15), average time in hyperglycemia decreased from42.39±23.32% to 31.58±16.65% (p=0. 019, N=14) and 14-day blood mean glucose decreased from 190.40±38.42 mg/dl to 167. 06±25.86 mg/dl (p=0. 001, N=17). There were no statistically significant differences in time in hypoglycemia and incidence of DKA. Hyperglycemic and hypoglycemic episodes were defined per patients’ individualized CGM settings (most commonly Blood Glucose levels>180 and <70 respectively). Patients’ weight decreased non-significantly from182. 00±50.92 lbs to 170.88±51.37 lbs (p=0.128, N=8). There were no ER visits or hospitalizations for DKA while on GLP-1 therapy. Conclusion There is an urgent need for strategies to improve glycemic control and reduce morbidity and mortality in T1DM. Long-acting GLP-1s are a promising adjunct to insulin. Our study is the first to demonstrate significant A1C reduction and TIR increase without increased hypoglycemia and DKA risk in 27 T1DM patients on long-acting GLP-1s. Longer prospective studies are warranted. Presentation: No date and time listed

Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes.

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes

Twice-Daily Pre-Mixed Insulin Rather Than Basal Insulin Therapy Alone Results In Better Overall Glycaemic Control In Patients With Type 2 Diabetes

Comparison of Insulin Intensification Strategies with Insulin Lispro Low Mixture Twice Daily Versus Basal Insulin Glargine and Prandial Insulin Lispro Once Daily in East Asian and Caucasian Patients with Type 2 Diabetes Mellitus.

Efficacy and safety of lispro insulin treatment in patients with type 2 diabetes mellitus:a Meta-analysis

Effect of Repaglinide and Gliclazide on Glycaemic Control, Early-Phase Insulin Secretion and Lipid Profiles In.

Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External Pumps

[Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment]

A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: Results of the PARADIGM study

Effects of Premixed Insulin Lispro versus Insulin Glargine on Type 2 Diabetes Mellitus: A Meta-Analysis

Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial

Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China

Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy

Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy

ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients

Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism

Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk

[Post-Hoc Analyses of Type 2 Diabetes Patients Switch from Premixed Insulin Regimen to Basal Insulin Plus Oral Hypoglycemic Agents Regimen].

Comparison of the Effect Between Insulin Lispro 75/25 and Humulin 70/30 on the Postprandial Blood Glucose Excursion in Patients with Diabetes

Ultra-rapid Lispro Improved Postprandial Glucose Control Compared to Insulin Lispro in Predominantly Chinese Patients with Type 1 Diabetes: A Prospective, Randomized, Double-Blind Phase 3 Study.

Efficacy and Safety of Insulin Glargine Combined with Glimepiride in Type 2 Diabetic Patients with Poor Glycemic Control